European Nod For Roche’s Ocrevus Clouded By Patient Limitation
Executive Summary
Swiss major Roche has finally got a positive opinion for its closely watched drug but concerns have been raised that Ocrevus will only be licensed for early-stage primary progressive multiple sclerosis patients.
You may also be interested in...
Pharma Q4 Results Preview: Pfizer, Merck, Roche, Amgen, Novo, Lilly, AstraZeneca
Leadership changes at Pfizer, immuno-oncology combination updates from Merck and Roche, and the potential for Novo Nordisk to make a new offer for Ablynx – plus other highlights from upcoming biopharma earnings calls.
EU CHMP OKs New Treatments For MS, Esophagitis, CMV, Hemophilia – & First Biosimilar Avastin
The EMA’s scientific committee, the CHMP, has given the green light to new treatments for multiple sclerosis, eosinophilic esophagitis, CMV, hemophilia A, and vaginal atrophy, as well as the EU’s first biosimilar version of Roche’s Avastin. The committee upheld two earlier negative opinions, and two products have been withdrawn from the assessment process.
MS Franchise A Surprising Concern For Sanofi In Q3; Dupixent Out-Performs
Sanofi produced a mixed financial performance in the third quarter of 2017, with reported sales more than €200m below analysts' expectations but new drug Dupixent doing well; MS drug sales have fallen since Q2 by more than €50m.